US Oncology, Inc. Affiliated Physicians to Present and Receive Honors at American Society of Clinical Oncology

May 21, 2010 |

4 min read

THE WOODLANDS, Texas, May 20 /PRNewswire/ -- US Oncology, Inc., the nation's leading integrated oncology company, announced today that two physicians affiliated with US Oncology Research will be honored at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 4 - 8 at McCormick Place in Chicago.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100520/DA08694)

Daniel D. Von Hoff, MD, FACP, is the recipient of the 2010 David A. Karnofsky Memorial Award and Lecture for his outstanding achievements in cancer research and for his impact on the treatment of patients with cancer. Dr. Von Hoff is an internationally recognized physician-scientist who has contributed to the development of numerous anticancer agents, including paclitaxel, docetaxel, irinotecan and gemcitabine. He currently serves as physician-in-chief for the Translational Genomics Institute in Phoenix, Arizona, chief scientific officer at US Oncology and Scottsdale Healthcare, and clinical professor of medicine at The University of Arizona College of Medicine. Dr. Von Hoff also serves as lead physician of the Translational Oncology Program (TOP) for US Oncology. The TOP program offers Phase I clinical trial studies, which often offer first-in-human agents. He is also responsible for bringing many new compounds to US Oncology Research for studies.

John V. Cox, DO, FACP, Texas Oncology is a recipient of the ASCO Statesman Award. This award recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Recipients of the 2010 Statesman Award have given 20 years of volunteer service.

In addition, more than 50 physicians affiliated with US Oncology Research and the United Network of US Oncology participated in studies that will be presented in oral and poster presentations at this year's ASCO. US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 40 FDA approved cancer fighting therapies.

Presentations that US Oncology affiliated physicians are part of include:

Oral Abstracts:
Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center:
	Tuesday, June 08, 9:30AM 12:30 PM (10:45 AM) E Hall D1
	A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC)

Joanne Blum, MD, PhD, Texas Oncology - Baylor Sammons Cancer Center
	Tuesday, June 08, 9:30 AM 12:30 PM (9:30 AM) E Hall D1
	A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.

Jeff Sharman, MD, Willamette Valley Cancer Institute and Research Center;
Kathryn Kolibaba, MD, Northwest Cancer Specialists - Vancouver Cancer Center
Thomas Boyd, MD, North Star Lodge Cancer Center, Yakima, Wash.
	Saturday, June 05, 1:00 4:00 PM (3:45 PM) E354a
	Effect of BTK inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study

William R. Berry, MD, Cancer Centers of North Carolina - Raleigh
	Sunday, June 06, 9:30 AM 12:30 PM (11:15 AM) E Hall D2
	Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial.


Late Breaking Oral Presentation:
Michael G. Teneriello, MD, Texas Oncology - Austin Central
	Sunday, June 06, 9:30 AM 12:30 PM (11:45 AM) E Arie Crown Theater
	Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report.


Clinical Science Symposium:
Daniel D. Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)
	Sunday, June 06, 8:00 AM 9:30 AM (8:45 AM) E345a
	Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors.


Donald A. Richards, MD, PhD, Texas Oncology Tyler
	Monday, June 07, 9:45 AM 11:15 AM (10:15 AM) E Arie Crown Theater
	Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.


Poster Discussions:
Michael G. Teneriello, MD, Texas Oncology - Austin Central
	Poster #5 Sunday , June 06, 2:00 PM 6:00 PM E450a
	Discussion 5:00 PM 6:00 PM E Arie Crown Theater
	PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer Poster discussion

Mark Fleming, MD, Virginia Oncology Associates - Hampton
Michael Kolodziej, MD, New York Oncology Hematology - Albany Medical Center
Sanjay Awasthi, MD, Texas Oncology - Arlington South
Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center
Danko Martincic, MD, Cancer Care Northwest Spokane Valley
Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center
Yunfei Wang;